All In Biotech

Drug Trial Radar · NCT06672146

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

A Randomized Phase II Trial of ASTX727 and Venetoclax Compared With ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults With IDH2 Mutant Acute Myeloid Leukemia: A MyeloMATCH Substudy

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

93

Planned (sponsor's estimate)

Start

May 16, 2025

Primary completion

Mar 31, 2027

Study completion Mar 31, 2027

Sponsor

Sponsor type
NIH
First posted
Nov 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II MyeloMATCH treatment trial studies how well ASTX727 and venetoclax plus enasidenib works compared to ASTX727 and venetoclax alone for the treatment of older patients with newly diagnosed acute myeloid leukemia (AML) or younger patients who are considered unfit for standard treatment, and who have an abnormal change (mutation) in the IDH2 gene. This gene mutation can cause AML to grow and spread. This trial is being done to see if adding enasidenib to the usual treatment can help more patients with the IDH2 gene get rid of AML. ASTX727 is a fixed-dose formulation of two drugs, cedazuridine and decitabine. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Enasidenib works by stopping the growth and spread of tumor cells that have the IDH2 mutation. Giving ASTX727 and venetoclax plus enasidenib may work better in treating AML patients with the IDH2 mutation.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Bone Marrow AspirationProcedure

    Undergo bone marrow aspiration

  • Bone Marrow BiopsyProcedure

    Undergo bone marrow biopsy

  • Decitabine and CedazuridineDrug

    Given PO

  • EnasidenibDrug

    Given PO

  • VenetoclaxDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Minimal residual disease negative (MRDneg) complete remission (CR) rateTime frame: Baseline to 5 years

Locations

138 sites in 2 countries. Site status is shown where the registry gives one.

  • Banner University Medical Center - Tucson

    Tucson, Arizona · Recruiting

  • University of Arizona Cancer Center-North Campus

    Tucson, Arizona · Recruiting

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas · Recruiting

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California · Active not recruiting

  • UCSF Medical Center-Parnassus

    San Francisco, California · Recruiting

  • Mills Health Center

    San Mateo, California · Active not recruiting

  • Memorial Regional Hospital/Joe DiMaggio Children's Hospital

    Hollywood, Florida · Suspended

  • Miami Cancer Institute

    Miami, Florida · Recruiting

  • Memorial Hospital West

    Pembroke Pines, Florida · Recruiting

  • Augusta University Medical Center

    Augusta, Georgia · Recruiting

  • Saint Luke's Cancer Institute - Boise

    Boise, Idaho · Recruiting

  • Kootenai Health - Coeur d'Alene

    Coeur d'Alene, Idaho · Recruiting

  • Saint Luke's Cancer Institute - Fruitland

    Fruitland, Idaho · Recruiting

  • Saint Luke's Cancer Institute - Meridian

    Meridian, Idaho · Recruiting

  • Saint Alphonsus Cancer Care Center-Nampa

    Nampa, Idaho · Recruiting

  • Saint Luke's Cancer Institute - Nampa

    Nampa, Idaho · Recruiting

  • Kootenai Clinic Cancer Services - Post Falls

    Post Falls, Idaho · Recruiting

  • Kootenai Clinic Cancer Services - Sandpoint

    Sandpoint, Idaho · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • University of Illinois

    Chicago, Illinois · Recruiting

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois · Recruiting

  • Northwestern Medicine Cancer Center Kishwaukee

    DeKalb, Illinois · Recruiting

  • NorthShore University HealthSystem-Evanston Hospital

    Evanston, Illinois · Recruiting

  • Northwestern Medicine Cancer Center Delnor

    Geneva, Illinois · Recruiting

  • NorthShore University HealthSystem-Glenbrook Hospital

    Glenview, Illinois · Recruiting

  • Northwestern Medicine Glenview Outpatient Center

    Glenview, Illinois · Recruiting

  • Northwestern Medicine Grayslake Outpatient Center

    Grayslake, Illinois · Recruiting

  • NorthShore University HealthSystem-Highland Park Hospital

    Highland Park, Illinois · Recruiting

  • Edward Hines Jr VA Hospital

    Hines, Illinois · Recruiting

  • Northwestern Medicine Lake Forest Hospital

    Lake Forest, Illinois · Recruiting

  • Loyola University Medical Center

    Maywood, Illinois · Recruiting

  • UC Comprehensive Cancer Center at Silver Cross

    New Lenox, Illinois · Recruiting

  • Northwestern Medicine Orland Park

    Orland Park, Illinois · Recruiting

  • University of Chicago Medicine-Orland Park

    Orland Park, Illinois · Recruiting

  • Northwestern Medicine Cancer Center Warrenville

    Warrenville, Illinois · Recruiting

  • UChicago Medicine Northwest Indiana

    Crown Point, Indiana · Recruiting

  • University of Kansas Clinical Research Center

    Fairway, Kansas · Recruiting

  • University of Kansas Cancer Center

    Kansas City, Kansas · Recruiting

  • University of Kansas Hospital-Westwood Cancer Center

    Westwood, Kansas · Recruiting

  • The James Graham Brown Cancer Center at University of Louisville

    Louisville, Kentucky · Recruiting

Showing 40 of 138 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.